CTRI/2017/10/010006进行中（未招募）2 期
A phase II non-randomized study to evaluate the efficacy of single dose rasburicase (1.5mg) in adult acute leukemia and high grade lymphomas with established tumor lysis syndrome
Tata Memorial Center0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Age >18yrs
- •2)ECOG PS 0-3
- •3)Newly diagnosed acute leukemia and high-grade lymphoma.
- •4)Laboratory or clinical TLS according to Cairo and Bishop Criteria.
排除标准
- •1) Patients with history of asthma or severe allergy
- •2)Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency
研究者
相似试验
进行中（未招募）
1 期
A Study in Older Patients Undergoing Elective Total Hip ReplacementDisuse atrophyMedDRA version: 14.1Level: LLTClassification code 10013521Term: Disuse muscle atrophySystem Organ Class: 100000004859EUCTR2011-000426-29-BEEli Lilly and Company384
进行中（未招募）
1 期
A Study in Older Patients Undergoing Elective Total Hip ReplacementDisuse atrophyMedDRA version: 14.1Level: LLTClassification code 10013521Term: Disuse muscle atrophySystem Organ Class: 100000004859EUCTR2011-000426-29-ATEli Lilly and Company384
进行中（未招募）
不适用
A Study in Older Patients Undergoing Elective Total Hip ReplacementDisuse atrophyMedDRA version: 14.1Level: LLTClassification code 10013521Term: Disuse muscle atrophySystem Organ Class: 100000004859EUCTR2011-000426-29-EEEli Lilly and Company384
进行中（未招募）
不适用
A Study in Older Patients who have fallen recently and have muscle weaknessDisuse atrophyMedDRA version: 14.1Level: LLTClassification code 10013521Term: Disuse muscle atrophySystem Organ Class: 100000004859EUCTR2011-006062-40-DEEli Lilly and Company172
进行中（未招募）
1 期
A Study in Older Patients Undergoing Elective Total Hip ReplacementDisuse atrophyMedDRA version: 14.1Level: LLTClassification code 10013521Term: Disuse muscle atrophySystem Organ Class: 100000004859EUCTR2011-000426-29-FREli Lilly and Company400